← Evidence library

BIB_327

Khattak A, Weber JS, Long GV, Schadendorf D, Carlino MS et al. (Mainz/BioNTech + Moderna + multicentre). KEYNOTE-942 5-year update: intismeran autogene (mRNA-4157) + pembrolizumab vs pembrolizumab alone in resected stage III/IV melanoma. ASCO 2025 + JCO Oncology Advances 2025. NCT03897881. Key number: 49% reduction in recurrence/death sustained at 5 years (HR 0.510, 95% CI 0.294-0.887, P = 0.0075). Phase III INTerpath-001 readout expected ~2027. [Tasks: 17, 18, 19b] Tier: 1 (ASCO + journal) Grade: A Retrieved: 2026-05-15

Evidence grade

A

Tier

1 (ASCO + journal)

Cited by tasks

17, 18, 19b

Identifiers

—

Full extracted findings & patient-implication analysis: bibliography/BIB_327/findings.md (research corpus). This page is a short context summary — not individualised medical advice.